

Attorney Docket No.: PTQ-0040
Inventors: Adams et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 10

A 4 concurred.
(ii) measuring invasiveness of said cells in an in vitro cellular assay; and

(iii) comparing the measured invasiveness to invasiveness of cells in a reference sample, wherein an increase in cell invasiveness relative to the reference sample is further indicative of increased risk of metastasis in the individual.

REMARKS

Claims 1 through 50 have been canceled without prejudice. New claims 51 through 89 have been added. These claims are drawn to subject matter restricted from parent application U.S. Serial No. 09/302,554 in the Restriction Requirement dated December 6, 1999. The subject matter is represented in new claims 51 through 89 using language preferred by the Examiner in the parent application. Support for new claims 51 through 89 is provided throughout the application and in particular in claims 37-40 and 48-50 as originally presented. Support is also provided, for example, in Figures 2A, 2B, 2C, 2D, 3A, 3B, 6, 7, 8, 10, 14, 16, 17, 20, 25A, 25B, 25C, and 25D; and in the specification at page 2, line 28, through page 3, line 11; page 13, lines 19-24; page 14, line 6, through page 15, line 25; page 17, lines 10-20; page 19, line 25-26, page 32, lines 15-26; page 36, line 8, through

Attorney Docket No.: PTQ-0040
Inventors: Adams et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 11

page 38, line 4; page 39, line 17, through page 41, line 15; and page 44, line 6, through page 46, line 23.

Applicants have also amended the specification at page 1 to reflect the priority status of this divisional application.

In addition, Applicants have amended the specification at page 6 and page 7 to correct inadvertent errors in the text. Specifically, at page 6, line 1, the term "Western" has been replaced with --Northern-- in accordance with teachings at page 38, lines 12-14 of the specification wherein results of Figure 4B are summarized as depicting mRNA levels. At page 7, line 4, the term "bolt" has been replaced with --blot-- to correct an inadvertent typographical error.

Accordingly, no new matter is added by this amendment and entry is respectfully requested.

Attached hereto, is a marked-up version of the changes made to the specification and claims by the current amendment. The

Attorney Docket No.: PTQ-0040
Inventors: Adams et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 13

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The first paragraph on page 1, beginning at line 2, has been amended as follows:

This application is a divisional of U.S. Patent Application Serial No. 09/302,554, filed April 30, 1999, which claims the benefit of priority of U.S. provisional application Serial No. 60/083,763, filed May 1, 1998, now abandoned, the entire teachings of which are herein incorporated by reference.

~~This application claims the benefit of Provisional Application No. 60/083,763, filed May 1, 1998, the entire teachings of which are incorporated herein by reference.~~

The paragraph on page 6, beginning at line 1, has been amended as follows:

Figure 4B is a ~~Western~~ Northern blot showing the effect of cobalt chloride, Tiron, and desferrioxamine mesylate (DFO) on the levels of RTP/Drg1 mRNA in MDA-MB-231 cells. Culture for up to 72 h, under 20% oxygen, in the presence of these compounds resulted in time-dependent increases in RTP/Drg1 mRNA. In a manner similar to hypoxic cultures, peak mRNA levels were

Attorney Docket No.: PTQ-0040
Inventors: Adams et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 14

observed after 24 h of culture. The data in this figure are representative of three independent experiments exhibiting similar results.

The paragraph on page 7, beginning at line 4, has been amended as follows:

Figure 8 is a Northern ~~bolt~~ blot showing increased expression of uPAR mRNA in cells cultured under hypoxic conditions. uPAR mRNA levels increased 2.5-fold after only 4 h of hypoxic culture compared with uPAR mRNA levels in cells cultured under standard conditions. The levels of uPAR transcript increased 5-fold at 6 h of culture under hypoxia and remained high at 8 and 24 h. Relative levels of uPAR mRNA were determined with a SigmaGel gel analysis program using 28S rRNA to correct for differences in the amount of RNA loaded onto the gel.

In the claims:

Please cancel claims 1 through 50 without prejudice.